GGrantIndex
← Search

ENBREL (TNFR:FC) TO TREAT OF IDIOPATHIC PULMONARY FIBROS

$0M01FY2000RRNIH

University Of Southern California, Los Angeles CA

Investigators

Linked publications & trials

Abstract

Current therapy for Idiopathice Pulmonary Fibrosis (IPF) is only partically effective in 25% of patients. Enbrel, recombinant human TNFR (TNFR:FC), binds both TNF and LT, which are inflamatory mediators, a more effective therapy for this ultimately fatan and not uncommond disease.

View original record on NIH RePORTER →